Incretin-based therapies from single to triple agonists offer increasingly effective MASLD/MASH treatment
Review of single (GLP-1RA), dual (GIP/GLP-1, GLP-1/glucagon), and triple (GIP/GLP-1/glucagon) incretin agonists for MASLD/MASH shows escalating efficacy with increasing receptor targeting, supported by phase 2 trials with histological improvements.
Quick Facts
What This Study Found
GLP-1RA (semaglutide): phase 3 for MASH. Dual agonists (tirzepatide, survodutide): phase 2 histological improvements. Triple agonist (retatrutide): most efficacy data emerging. Escalating efficacy with more receptor targets. Hepatoprotective beyond weight loss.
Key Numbers
How They Did This
Narrative review of clinical trial evidence for single, dual, and triple incretin agonists in MASLD/MASH.
Why This Research Matters
MASLD/MASH has had no approved pharmacotherapy until recently. Incretin-based drugs offer the first effective treatment class, with escalating potency as more receptor targets are engaged.
The Bigger Picture
The MASLD treatment paradigm is shifting from "no drugs available" to "which combination of incretin receptors to target." This progression from single to triple agonism may define the next decade of liver disease treatment.
What This Study Doesn't Tell Us
Most evidence from phase 2 trials. Long-term liver outcome data limited. Optimal receptor combination unclear. Not all patients respond equally.
Questions This Raises
- ?Will triple agonists prove more effective than dual for MASH?
- ?Is the glucagon component essential for liver fat reduction?
- ?Should incretin drugs be combined with resmetirom for comprehensive MASH treatment?
Trust & Context
- Key Stat:
- Escalating efficacy: single → dual → triple Incretin-based liver therapies show increasing MASH efficacy as more receptor targets are engaged—from GLP-1 alone through dual to triple agonists
- Evidence Grade:
- Narrative review of phase 2/3 clinical trial evidence. Growing but not yet definitive evidence base.
- Study Age:
- Published in 2025.
- Original Title:
- Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.
- Published In:
- Gut, 74(3), 487-497 (2025)
- Authors:
- Targher, Giovanni(4), Mantovani, Alessandro(3), Byrne, Christopher D(3), Tilg, Herbert
- Database ID:
- RPEP-13775
Evidence Hierarchy
Frequently Asked Questions
Are there drugs for fatty liver disease?
Yes, and they are improving rapidly. GLP-1 drugs like semaglutide are in advanced clinical trials for MASH (advanced fatty liver). Newer drugs targeting 2 or 3 incretin receptors simultaneously (tirzepatide, survodutide, retatrutide) show even greater liver improvement in early trials.
Why do more receptor targets help?
Different incretin receptors address different aspects of liver disease: GLP-1 reduces appetite and inflammation, GIP improves fat handling, and glucagon increases energy expenditure and directly clears liver fat. Combining these effects produces increasingly powerful liver improvement.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13775APA
Targher, Giovanni; Mantovani, Alessandro; Byrne, Christopher D; Tilg, Herbert. (2025). Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.. Gut, 74(3), 487-497. https://doi.org/10.1136/gutjnl-2024-334023
MLA
Targher, Giovanni, et al. "Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.." Gut, 2025. https://doi.org/10.1136/gutjnl-2024-334023
RethinkPeptides
RethinkPeptides Research Database. "Recent advances in incretin-based therapy for MASLD: from si..." RPEP-13775. Retrieved from https://rethinkpeptides.com/research/targher-2025-recent-advances-in-incretinbased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.